Medicare beneficiaries facing metastatic prostate cancer need to know which parts of Medicare actually cover Xofigo’s $50,000+ treatment cost—and surprisingly, it’s not the part most people expect.
Key Takeaways
- Medicare Part A and Part B both cover Xofigo for eligible beneficiaries when medically necessary, though coverage depends on where treatment is administered.
- Part D prescription plans do not cover Xofigo since it’s administered as an injectable treatment rather than a traditional prescription medication.
- Between 2015-2017, Medicare spent over $133 million on Xofigo therapy, demonstrating significant coverage commitment for this specialized cancer treatment.
- Multiple financial assistance programs are available to help reduce out-of-pocket costs for Medicare beneficiaries requiring Xofigo treatment.
- Understanding specific coverage requirements and documentation needs can help ensure successful Medicare approval for this radiopharmaceutical therapy.
For Medicare beneficiaries facing metastatic prostate cancer that has spread to the bones, understanding coverage options for specialized treatments like Xofigo becomes crucial for accessing potentially life-extending care. This radiopharmaceutical represents an important treatment option, but navigating Medicare’s complex coverage landscape requires careful attention to specific requirements and available support programs.
Medicare Part A and Part B Both Cover Xofigo
Medicare provides coverage for Xofigo (radium Ra 223 dichloride) through both Part A and Part B, depending on where patients receive their treatment. This radiotherapeutic infusion, approved for treating metastatic, castration-resistant prostate cancer, falls under Medicare’s medical coverage rather than prescription drug benefits. Medicare.org provides detailed resources to help beneficiaries understand their coverage options and navigate the approval process for specialized cancer treatments.
Part A Coverage in Skilled Nursing Facilities
When Xofigo treatment occurs during an inpatient hospital stay or in a skilled nursing facility, Medicare Part A typically covers the costs. This coverage applies when patients require hospitalization for their cancer treatment or when medical complications necessitate inpatient monitoring during radiopharmaceutical therapy. Part A coverage includes the medication itself, administration costs, and related hospital services during the stay.
Part B Coverage in Outpatient Settings
Most Xofigo treatments occur in outpatient settings, making Medicare Part B the primary coverage source for this therapy. Part B covers the radiopharmaceutical when administered in hospital outpatient departments, cancer treatment centers, or physician offices equipped to handle radioactive medications. Beneficiaries typically pay 20% coinsurance after meeting their annual Part B deductible, which is $257 in 2025.
Medicare Part D Does Not Cover Xofigo
Understanding why Medicare Part D doesn’t cover Xofigo helps beneficiaries avoid confusion about their coverage options and ensures they look to the correct Medicare components for treatment authorization.
Injectable Treatment Exclusion
Medicare Part D specifically excludes injectable treatments that are administered by healthcare providers in clinical settings. Since Xofigo requires specialized handling due to its radioactive properties and must be given as a 1-minute intravenous injection by trained medical professionals, it falls outside Part D’s coverage scope. This exclusion applies to all radiopharmaceuticals and similar injectable cancer treatments that cannot be self-administered at home.
Where to Get Coverage Instead
Beneficiaries should focus their coverage efforts on Medicare Parts A and B rather than seeking Part D approval for Xofigo. The treatment’s classification as a medical procedure rather than a traditional prescription medication means it follows the same coverage pathways as other cancer therapies like chemotherapy infusions or radiation treatments. Prior authorization may be required, and documentation of medical necessity becomes crucial for approval.
What Medicare Spent on Xofigo Treatment
Medicare’s investment in Xofigo therapy demonstrates the program’s commitment to covering innovative cancer treatments, even when they carry significant costs for the healthcare system.
Historic $133 Million Investment (2015-2017)
Between 2015 and 2017, Medicare spent over $133 million on Xofigo therapy, with radiation oncologists managing the majority of these specialized infusions. This substantial investment reflects both the treatment’s effectiveness for eligible patients and Medicare’s recognition of its medical necessity for advanced prostate cancer care. The spending pattern shows consistent growth as more providers became qualified to administer the treatment and awareness increased among oncology specialists.
Treatment Cost Range for Beneficiaries
Studies estimate complete Xofigo treatment costs between $43,000 and $57,000 for a standard six-cycle regimen, though actual costs may vary based on individual circumstances and treatment centers. While Medicare covers the majority of these costs, beneficiaries typically face coinsurance obligations of 20% under Part B coverage. For a complete treatment course, this could mean out-of-pocket costs ranging from $8,600 to $11,400, depending on the total treatment expenses and whether patients have supplemental insurance coverage.
Financial Assistance Programs Available
Multiple assistance programs help Medicare beneficiaries manage the substantial out-of-pocket costs associated with Xofigo treatment, ensuring financial barriers don’t prevent access to this potentially life-extending therapy.
1. Patient Access Network Foundation
The Patient Access Network Foundation (PAN) assists eligible patients with unaffordable copays or deductibles for Xofigo treatment. To qualify, patients must have income below 400% of the federal poverty level and receive Xofigo prescriptions for approved FDA indications. PAN’s program specifically addresses the gap between Medicare coverage and remaining patient responsibilities, helping bridge significant financial obstacles.
2. Bayer’s Xofigo Access Services
Bayer, Xofigo’s manufacturer, operates the Xofigo Access Services program to support patient access. This program may provide the medication free of charge to eligible uninsured patients or those whose insurance doesn’t cover Xofigo. While Medicare beneficiaries cannot access certain manufacturer copay programs due to federal regulations, they may qualify for other forms of assistance through this manufacturer program.
3. HealthWell Foundation Copay Program
The HealthWell Foundation operates copay assistance programs for various cancer treatments, including specialized therapies like Xofigo. Their programs help eligible patients with insurance copayments, coinsurance, and deductibles when they face financial hardship. Medicare beneficiaries should inquire about current program availability, as funding and eligibility requirements change periodically.
4. Independent Copay Assistance Foundations
Several independent foundations provide copay and coinsurance assistance specifically for Medicare beneficiaries who need help with cost-sharing requirements. These programs operate separately from manufacturer assistance programs and focus exclusively on helping patients with government insurance coverage. Eligibility typically depends on income levels and specific disease criteria.
Understanding Xofigo Treatment Requirements
Successful Medicare coverage for Xofigo depends on meeting specific medical criteria and following established treatment protocols that demonstrate medical necessity.
Qualifying Cancer Conditions
Xofigo treats prostate cancer that no longer responds to hormonal or surgical treatment and has spread to the bone with symptoms, but not to other visceral organs. The cancer must be castration-resistant, meaning standard testosterone-lowering treatments have become ineffective. Medicare requires clear documentation that other treatments haven’t been effective or that physicians consider Xofigo the optimal treatment choice for the patient’s specific condition.
Administration Process
The medication is administered as a 1-minute intravenous injection in specialized facilities equipped to handle radioactive materials. Treatment centers must have proper radiation safety protocols, trained staff, and appropriate disposal methods for radioactive waste. This specialized administration requirement supports Medicare’s coverage under medical benefits rather than prescription drug programs.
Treatment Schedule
Standard Xofigo therapy involves one injection every 4 weeks for a total of 6 injections. This treatment schedule spans approximately 5 months, requiring consistent patient monitoring and regular medical assessments. Medicare coverage typically follows this established protocol, though individual treatment plans may vary based on patient response and side effect management.
Side Effects Medicare Beneficiaries Should Monitor
Understanding Xofigo’s side effect profile helps Medicare beneficiaries prepare for treatment and recognize when medical attention becomes necessary during their therapy course.
Common Side Effects
Xofigo commonly causes nausea, diarrhea, vomiting, peripheral edema, anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia. These side effects reflect the medication’s impact on both cancer cells and healthy tissue, particularly bone marrow where blood cells are produced. Patients should expect regular blood monitoring throughout treatment to track blood cell counts and adjust treatment timing if necessary.
Serious Complications
Serious complications include dehydration from diarrhea and vomiting, which requires prompt medical attention and fluid monitoring. The treatment can cause kidney function problems and potentially dangerous drops in blood cell counts that increase infection risk. Medicare beneficiaries should understand that managing these complications is covered under their medical benefits, including emergency care, hospitalizations, and supportive treatments needed to address severe side effects.
Medicare Coverage Requires Medical Necessity Documentation
Medicare coverage approval for Xofigo depends on detailed medical documentation that demonstrates the treatment’s necessity and appropriateness for each individual patient’s condition. Physicians must provide detailed records showing previous treatment failures, current disease status, and evidence that Xofigo represents the most appropriate therapeutic option. This documentation process includes pathology reports, imaging studies, treatment history, and physician assessments that support the medical necessity determination. Proper documentation ensures smoother approval processes and reduces the likelihood of coverage denials that could delay critical treatment.